GSK's $3 Billion Settlement Reflects Continued Expansion In Scope Of Pharma Plea Agreements

August 2012
Rx Compliance Report
On July 2, 2012, the U.S. Justice Department (DOJ) announced that GlaxoSmithKline LLC (GSK) had agreed to plead guilty to three misdemeanors under the Food, Drug, and Cosmetic Act and to pay $3 billion to resolve criminal and civil liability relating to allegations concerning the promotion of nine drugs, failure to report safety data for the drug Avandia, and failure to report on the "best price" for certaind drugs.